biomarker development News
-
Commitment to Access, Quality and Growth through Innovation
Dynacare Launches JOINTstat® Testing in Canada Augurex is pleased to announce the launch of JOINTstat (14-3-3?) testing services through Dynacare, one of Canada’s largest and most established health solution companies with a dedicated mission to support healthy lives with commitment and care. This arrangement will make JOINTstat testing accessible to more patients and physicians ...
-
Aurora BioPharma To Join In On A Presentation And Discussion On The GBM AGILE Trial At The Ritz-Carlton, Pentagon City
Aurora BioPharma, Inc., a clinical stage biotechnology company developing a breakthrough in cancer treatment, announced today that company CEO and President, Robert Brooks, will join in on a presentation and discussion of the GBM AGILE (Adaptive, Global, Innovative, Learning Environment) trial. The meeting is being held at the Ritz Carlton, at Fashion Centre at Pentagon City, April 11th. About ...
-
GI Innovation singed MoU with CellKey for joint biomarker research for development of next generation innovative immuno-oncology.
Joint research of biomarkers on platform technology of GI Innovation, GI-SMARTTM and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next generation immuno-oncology, personalized cancer treatment effects… increasing Reliability and efficiency of treatment GI Innovation, a new innovative drug development company, announced on February ...
-
GI Innovation Signs MoU with CellKey for Biomarker Joint Research to Develop Next-generation Innovative Immuno-oncology
Joint research of biomarkers on platform technology of GI Innovation, GI-SMART™, and SpAC9 Pipeline, AI-powered biomarker discovery platform of CellKey Prediction of drug response on next-generation immuno-oncology, personalized cancer treatment effects… increasing reliability and efficiency of treatment GI Innovation, an innovative new drug development company, announced on ...
-
Immunai Acquires Swiss Bioinformatics Firm Nebion
New York City- and Tel Aviv-based Immunai said the acquisition would allow it to expand its target discovery and drug development capabilities and that Nebion's experience curating public gene expression datasets would help Immunai grow its Annotated Multiomic Immunological Cell Atlas, or AMICA. "As with other machine learning endeavors like autonomous driving or NLP, having the right data is ...
By Immunai
-
Showcase
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Cellphire Therapeutics Appoints Pamela B. Conley to its Board of Directors
Cellphire Therapeutics, Inc., a biotechnology company developing next-generation allogeneic cellular therapeutics for application across multiple medical indications, announced today the appointment of Pamela B. Conley, Ph.D. to the company’s Board of Directors. “Pam is a terrific addition to our Board,” said Mike Gaffney, Chief Executive Officer. “Her work leading the ...
-
Regeneus partners with ASTEM to improve efficiencies in adipose tissue donor selection
Regeneus has partnered with the Allogeneic STEM cell manufacturing Programme (ASTEM) to investigate the status of a novel genomic biomarker within their adipose donor banks. This work is being conducted at one of the partner institutes of the ASTEM Programme, the Genome Institute of Singapore, which is a leading Research Institute within the Agency for Science, Technology and Research ...
-
Actym Therapeutics, Inc. today announced the appointment of Chan Whiting, Ph.D. as Chief Development Officer
Actym Therapeutics hires Dr. Chan Whiting as Chief Development Officer. Chan brings over 20 years of drug development experience within the biotechnology industry. As CDO, Chan will play a key leadership role in advancing Actym's pipeline of first-in-class, systemically administered therapeutics that re-program the immunosuppressive microenvironment in solid tumors. "Chan has significant ...
-
Alzheimer’s Drug Discovery Foundation’s diagnostics accelerator announces first digital biomarker research award and data sharing platform
Digital biomarker awards support technology solutions for early detection of Alzheimer’s and related dementias Data platform enables researchers using digital tools to share their findings for benchmarking, analysis and use across research projects ADDF’s Diagnostics Accelerator has $50 million in commitments from leading philanthropists Leonard A. Lauder, Bill Gates, Jeff Bezos ...
-
INOVIO Highlights Key Updates on Phase 3 Program for VGX-3100, its DNA-based Immunotherapy for the Treatment of Cervical HSIL Caused by HPV-16 and/or HPV-18
INOVIO (NASDAQ: INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to help protect people from infectious diseases and treat cancer and HPV-associated diseases, today announced updates on the Phase 3 program for VGX-3100 for HPV-associated cervical high-grade squamous intraepithelial lesions (HSIL), including a one-year follow-up of efficacy and safety ...
-
MicrobioSeq Announces the Launch of the Phage Whole-Genome Sequencing Service
MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics is a genomics service company with a good reputation for providing reliable sequencing, genotyping, microarray, and bioinformatics services. The company has launched the Phage Whole-Genome Sequencing to help discover biomarkers and develop non-antibiotic treatment methods. Phages ...
By CD Genomics
-
Agilent Technologies and Seoul National University hospital collaborate on biomarker research
Agilent Technologies Inc. (NYSE: A) and Seoul National University Hospital, one of Korea's top medical centers, today announced a strategic collaboration for the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers. "There are gaps in the medical industry that hamper the quality of care we can provide to ...
-
Empatica and BARDA Join Forces to Validate Wearable System That Detects COVID-19 Before Symptoms Appear
BOSTON, June 19, 2020 /PRNewswire/ -- Digital healthcare company Empatica announces a pioneering new partnership with the Biomedical Advanced Research and Development Authority ("BARDA"), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services (HHS), to validate an early warning system for COVID-19 and other respiratory ...
-
Treos Bio Announces FDA Clearance of IND Application for PolyPEPI1018 Immunotherapy for the Treatment of Metastatic Colorectal Cancer
LONDON, August 18, 2021– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop both precision off-the-shelf and personalized peptide immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PolyPEPI1018, the ...
-
Ariana announces an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi
Ariana® Pharma a leading Artificial Intelligence drug development company announced today that it has entered into an Artificial Intelligence-driven Precision Medicine collaboration with Sanofi and leading academic partners targeting autoimmune and inflammatory diseases associated with primary immune deficiencies. The ATRACTion project will generate clinical, multi-omic (single cell RNA ...
-
MODAG Successfully Completes Phase 1 Study of their Lead Candidate Anle138b and Receives Additional USD 1.4 Million from Michael J. Fox Foundation
MODAG, a German biotechnology company focused on the development of disease-modifying small molecule therapeutics for neurodegenerative diseases, today announced the successful completion of its first clinical trial of anle138b (NCT04208152) in healthy volunteers. The Company’s lead candidate, which was administered in doses of up to 300 mg daily, demonstrated excellent safety and ...
By MODAG GmbH
-
SARS-CoV-2 Glycosylation Profiling Service Now Available at CD BioGlyco
CD BioGlyco, a biotechnology company that offers a full range of glycobiology-related products, analysis, custom synthesis, and design to help advance glycobiology research, now provides customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents during this COVID-19 pandemic. The US FDA has approved Pfizer and ...
By CD BioGlyco.
-
Agilent Technologies and Chungnam National University collaborate to further glycomics research
Agilent Technologies Inc. (NYSE: A) and Chungnam National University today announced an agreement to develop new applications, methods, technologies and software tools in the field of glycomics, the study of complex sugars. The university aims to identify and develop biomarkers for diseases such as cancer, leading to development of therapeutic antibody products. This announcement marks the first ...
-
Treos Bio Enters into Clinical Collaboration to Evaluate its Polypeptide Cancer Immunotherapy PolyPEPI1018 in Combination with Roche’s PD-L1-Inhibitor
LONDON, July 7, 2021– Treos Bio Limited (“Treos”), a clinical stage biotechnology company using data science and proprietary biomarkers to develop both precision off-the-shelf and personalized peptide cancer immunotherapies, today announced a clinical collaboration with Roche in which Treos will evaluate the combination of PolyPEPI1018, its lead product candidate, and ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you